Skip to main content

In clinical studies, patients have occasionally experienced nausea during PhosLo (calcium acetate tablet) therapy. Hypercalcemia may occur during treatment with PhosLo (calcium acetate tablet) . Mild hypercalcemia (Ca>10.5mg/dL) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. More severe hypercalcemia (Ca>12mg/dl) is associated with confusion, delirium, stupor and coma. Mild hypercalcemia is easily controlled by reducing the PhosLo (calcium acetate tablet) dose or temporarily discontinuing therapy. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing PhosLo (calcium acetate tablet) therapy. Decreasing dialysate calcium concentration could reduce the incidence and severity of PhosLo (calcium acetate tablet) induced hypercalcemia. The long-term effect of PhosLo (calcium acetate tablet) on the progression of vascular or soft-tissue calcification has not been determined.

Isolated cases of pruritus have been reported which may represent allergic reactions.